and Hematology Research, National Institutes of Health.)

Dated: February 24, 1998.

LaVerne Stringfield,

NIH Committee Management Officer. [FR Doc. 98–5570 Filed 3–3–98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute on Drug Abuse (NIDA) Special Emphasis Panel (SEP) meetings.

Purpose/Agenda: To review and evaluate grant applications and contract proposals.

Name of Committee: NIDA Special Emphasis Panel (Treatment).

Date: March 3, 1998.

Time: 10:00 a.m.

Place: Double Tree Hotel, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: Rita Liu, Ph.D., Scientific Review Administrator, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10–22, Telephone (301) 443–9042.

Name of Committee: NIDA Special Emphasis Panel (Contract Review— "Technical and Logistical Support Assistance to NIDA, OSPC").

Date: March 5, 1998.

Time: 9:30 a.m.

Place: Parklawn Building, Conference Q, 3rd Floor, 5600 Fishers Lane, Rockville, MD 20857.

Contact Person: Mr. Lyle Furr, Review Administrator, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10–42, Telephone (301) 443–1644.

Name of Committee: NIDA Special Emphasis Panel (AIDS Biomedical and Clinical).

Date: March 11, 1998.

Time: 11:00 a.m.

Place: Holiday Inn Bethesda, 8120 Wisconsin Avenue, Bethesda, MD 20852.

Contact Person: Khursheed Asghar, Ph.D., Scientific Review Administrator, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10–42, Telephone (301) 443–2620.

Name of Committee: NIDA Special Emphasis (AIDS Biomedical and Clinical). Date: March 11, 1998.

Time: 2:00 p.m.

Place: Holiday Inn Bethesda, 8120 Wisconsin Avenue, Bethesda, MD 20852. Contact Person: Khursheed Asghar, Ph.D., Scientific Review Administrator, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10–42, Telephone (301) 443–2620. This notice is being published less than 15 days prior to the meetings due to the urgent need to meet timing limitations imposed by the review and funding cycle.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Programs Nos. 93.277, Drug Abuse Research Scientist Development and Research Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse Research Programs.)

Dated: February 24, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH. [FR Doc. 98–5571 Filed 3–3–98; 8:45 am] BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Amended Notice of Closed Meeting

Notice is hereby given of a change in the meeting of the National Institute on Drug Abuse Special Emphasis Panel (Organization and Management of Drug Abuse Treatment Services) on March 4, 1998, at 8:30 a.m., at the Key Bridge Marriott Hotel, 1401 Lee Highway, Arlington, VA 22209, which was published in the **Federal Register** on January 26, 1998, Volume 63, FR 6575.

The date and time of this committee have been changed to March 3, 1998, at 2:00 p.m.

Dated: February 24, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH. [FR Doc. 98–5572 Filed 3–3–98; 8:45 am] BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Amended Notice of Closed Meetings

Notice is hereby given of changes in the National Institute on Drug Abuse (NIDA) Initial Review Group and Special Emphasis Panel meetings, which was published in the **Federal Register** on January 26, 1998, Volume 63, FR 3756. The NIDA Special Emphasis Panel (Training and Career Development) on March 2–4, 1998, at 8:30 a.m., at the Residence Inn by Marriott, 7335 Wisconsin Avenue, Bethesda, MD 20814.

The dates and location of this committee have been changed to April 6–8, 1998, at the Ritz-Carlton at Pentagon City, 1250 South Hayes Street, Arlington, VA 22202.

The AIDS Biomedical and Clinical Research Subcommittee on March 10– 11, 1998, at 8:30 a.m., at the Double Tree Hotel, 1750 Rockville Pike, Rockville, MD 20852.

The location of this committee has been changed to Bethesda Holiday Inn, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Dated: February 24, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH. [FR Doc. 98–5573 Filed 3–3–98; 8:45 am] BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of General Medical Sciences; Notice of Meeting of the National Advisory General Medical Sciences Council

Pursuant to Pub. L. 92–463, notice is hereby given of the meeting of the National Advisory General Medical Sciences Council, National Institute of General Medical Sciences, National Institutes of Health, on May 14–15, 1998, Natcher Building 45, Conference Rooms E1 and E2, Bethesda, Maryland.

This meeting will be open to the public from 11 a.m. to 6 p.m. on May 14, for the discussion of program policies and issues, opening remarks, report of the Director, NIGMS, and other business of Council. Attendance by the public will be limited to space available.

In accordance with provisions set forth in secs. 552b(c)(4) and 552b(c)(6). Title 5, U.S.C. and sec. 10(d) of Pub. L. 92-463, the meeting will be closed to the public on May 14, from 8:30 a.m. to 11:00 a.m., and also closed on May 15, (8:30 a.m. to adjournment) for the review, discussion, and evaluation of individual grant applications. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications, disclosure of which would constitute a clearly unwarranted invasion of personal privacy.